NxStage Medical Company Profile (NASDAQ:NXTM)

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical logoNxStage Medical, Inc. is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. The In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis, primarily for the treatment of end-stage renal disease patients at dialysis clinics, and needles for apheresis. It markets extracorporeal disposable products under the Medisystems brand. The Services segment includes revenues from dialysis services provided to patients at its NxStage Kidney Care dialysis centers. Its product offerings include Home Dialysis, Next-Generation Hemodialysis System, Critical Care, Next-Generation Critical Care System and In-Center.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Imaging Systems
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:NXTM
  • CUSIP: 67072V10
  • Web: www.nxstage.com
Capitalization:
  • Market Cap: $1.54 billion
  • Outstanding Shares: 65,735,000
Average Prices:
  • 50 Day Moving Avg: $24.03
  • 200 Day Moving Avg: $25.95
  • 52 Week Range: $20.45 - $30.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 212.45
  • P/E Growth: -39.88
Sales & Book Value:
  • Annual Revenue: $374 million
  • Price / Sales: 4.11
  • Book Value: $3.20 per share
  • Price / Book: 7.30
Profitability:
  • EBIDTA: $14.68 million
  • Net Margins: -1.25%
  • Return on Equity: -2.31%
  • Return on Assets: -1.47%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 3.17%
  • Quick Ratio: 2.15%
Misc:
  • Average Volume: 617,541 shs.
  • Beta: 0.09
  • Short Ratio: 4.74
 
Frequently Asked Questions for NxStage Medical (NASDAQ:NXTM)

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $96.83 million for the quarter, compared to the consensus estimate of $95.31 million. NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. NxStage Medical's revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) earnings per share. View NxStage Medical's Earnings History.

Where is NxStage Medical's stock going? Where will NxStage Medical's stock price be in 2017?

5 equities research analysts have issued 1-year price targets for NxStage Medical's shares. Their predictions range from $27.00 to $35.00. On average, they expect NxStage Medical's stock price to reach $31.80 in the next twelve months. View Analyst Ratings for NxStage Medical.

What are analysts saying about NxStage Medical stock?

Here are some recent quotes from research analysts about NxStage Medical stock:

  • 1. Jefferies Group LLC analysts commented, "Home hemodialysis (HHD) in skilled nursing facilities (SNF) is a significant opportunity for NXTM. HHD penetration is already approaching 6% in the most developed states v. less than 2% for the market as a whole; a disparity explained to a large degree by SNF adoption. The regulatory underpinnings can be debated, but even modest assumptions for continued adoption in SNFs supports 20%+ revenue growth at NXTM. We raise our PT to $38, 5x 2018 sales." (2/6/2017)
  • 2. According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (1/5/2017)

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:

  • Robert G. Funari, Independent Chairman of the Board
  • Joseph E. Turk Jr., President
  • Jeffrey H. Burbank, Chief Executive Officer, Director
  • Matthew W. Towse CPA, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
  • Robert S. Brown, President of NxStage Kidney Care
  • Winifred L. Swan J.D., Senior Vice President, General Counsel
  • Heyward R. Donigan, Independent Director
  • Daniel A. Giannini CPA,, Independent Director
  • Earl R. Lewis, Independent Director
  • Jean K. Mixer, Independent Director

Who owns NxStage Medical stock?

NxStage Medical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.49%), CWM LLC (0.16%), Sit Investment Associates Inc. (0.07%), Capital Impact Advisors LLC (0.05%), Parkwood LLC (0.03%) and Russell Investments Group Ltd. (0.03%). Company insiders that own NxStage Medical stock include Barry M Straube, Craig W Moore, Daniel A Giannini, Earl R Lewis, Jeffrey H Burbank, Joseph E Turk Jr, Joseph E Turk, Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Who sold NxStage Medical stock? Who is selling NxStage Medical stock?

NxStage Medical's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC, Russell Investments Group Ltd., Aperio Group LLC and US Bancorp DE. Company insiders that have sold NxStage Medical stock in the last year include Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Insider Buying and Selling for NxStage Medical.

Who bought NxStage Medical stock? Who is buying NxStage Medical stock?

NxStage Medical's stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, CWM LLC, Parkwood LLC, Sit Investment Associates Inc. and Quantitative Systematic Strategies LLC. Company insiders that have bought NxStage Medical stock in the last two years include Barry M Straube and Earl R Lewis. View Insider Buying and Selling for NxStage Medical.

How do I buy NxStage Medical stock?

Shares of NxStage Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NxStage Medical stock can currently be purchased for approximately $23.37.


MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  301
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NxStage Medical (NASDAQ:NXTM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $31.80 (36.07% upside)

Analysts' Ratings History for NxStage Medical (NASDAQ:NXTM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/27/2017Craig HallumInitiated CoverageBuy$32.00HighView Rating Details
5/10/2017Jefferies Group LLCLower Price TargetBuy$38.00 -> $33.00MediumView Rating Details
5/10/2017BTIG ResearchReiterated RatingBuy$27.00LowView Rating Details
5/8/2017Canaccord GenuityReiterated RatingBuy$32.00HighView Rating Details
5/4/2017Northland SecuritiesDowngradeOutperform -> Market PerformMediumView Rating Details
6/3/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00N/AView Rating Details
5/5/2016Wells Fargo & CompanyReiterated RatingSellN/AView Rating Details
12/11/2015Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
11/4/2015Leerink SwannBoost Price Target$24.00 -> $30.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for NxStage Medical (NASDAQ:NXTM)
Earnings by Quarter for NxStage Medical (NASDAQ:NXTM)
Earnings History by Quarter for NxStage Medical (NASDAQ NXTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.03)($0.02)$95.31 million$96.83 millionViewListenView Earnings Details
2/28/2017Q416($0.02)($0.02)$91.82 million$93.01 millionViewListenView Earnings Details
8/4/2016Q216($0.04)($0.03)$89.44 million$92.20 millionViewN/AView Earnings Details
5/4/2016Q116($0.05)($0.02)$88.40 million$89.20 millionViewListenView Earnings Details
2/10/2016Q415($0.04)($0.04)$86.83 million$89.80 millionViewListenView Earnings Details
11/3/2015Q315($0.08)($0.03)$82.06 million$86.50 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.08)$79.89 million$80.30 millionViewListenView Earnings Details
5/6/2015Q115($0.11)($0.09)$77.92 million$79.50 millionViewListenView Earnings Details
2/26/2015Q414($0.10)($0.08)$75.75 million$79.90 millionViewListenView Earnings Details
11/6/2014Q3($0.13)($0.07)$71.83 million$75.30 millionViewN/AView Earnings Details
8/7/2014Q214($0.11)($0.12)$70.52 million$74.10 millionViewN/AView Earnings Details
5/8/2014Q114($0.11)($0.09)$69.44 million$72.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.08)$67.66 million$69.40 millionViewN/AView Earnings Details
11/7/2013Q313$0.22($0.08)$124.03 million$66.90 millionViewListenView Earnings Details
7/25/2013Q2 2013($0.07)($0.06)$64.66 million$65.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.08)($0.08)$61.14 million$61.60 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.05)($0.04)$63.54 million$65.00 millionViewN/AView Earnings Details
11/8/2012Q312($0.06)($0.04)$60.90 million$61.00 millionViewN/AView Earnings Details
8/8/2012($0.09)($0.09)ViewN/AView Earnings Details
5/8/2012($0.09)($0.09)ViewN/AView Earnings Details
2/29/2012($0.09)($0.08)ViewN/AView Earnings Details
11/3/2011($0.10)($0.10)ViewN/AView Earnings Details
8/3/2011($0.10)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NxStage Medical (NASDAQ:NXTM)
2017 EPS Consensus Estimate: ($0.03)
2018 EPS Consensus Estimate: $0.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)($0.02)($0.02)
Q2 20173($0.03)$0.00($0.02)
Q3 20173($0.01)$0.01$0.00
Q4 20173$0.00$0.03$0.01
Q1 20182$0.01$0.02$0.02
Q2 20182$0.01$0.04$0.03
Q3 20182$0.03$0.06$0.05
Q4 20182$0.05$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NxStage Medical (NASDAQ:NXTM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NxStage Medical (NASDAQ:NXTM)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 95.43%
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Matthew W TowseSVPSell4,300$24.16$103,888.00View SEC Filing  
7/5/2017Joseph E Turk JrPresidentSell1,000$25.19$25,190.00View SEC Filing  
6/20/2017Matthew W TowseSVPSell4,300$23.29$100,147.00View SEC Filing  
6/15/2017Winifred L SwanSVPSell3,500$23.14$80,990.00View SEC Filing  
6/14/2017Joseph E Turk JrPresidentSell1,000$23.74$23,740.00View SEC Filing  
5/22/2017Matthew W TowseSVPSell4,300$21.36$91,848.00View SEC Filing  
5/15/2017Winifred L SwanSVPSell3,500$21.94$76,790.00View SEC Filing  
5/10/2017Joseph E Turk JrPresidentSell250$23.59$5,897.50View SEC Filing  
5/3/2017Joseph E Turk JrPresidentSell1,000$29.95$29,950.00View SEC Filing  
4/20/2017Jeffrey H BurbankCEOSell3,000$27.28$81,840.00View SEC Filing  
4/20/2017Matthew W TowseSVPSell4,300$27.28$117,304.00View SEC Filing  
4/19/2017Jeffrey H BurbankCEOSell3,000$26.65$79,950.00View SEC Filing  
4/13/2017Joseph E Turk JrPresidentSell1,000$26.10$26,100.00View SEC Filing  
4/3/2017Robert S BrownInsiderSell14,397$26.60$382,960.20View SEC Filing  
3/22/2017Jeffrey H BurbankCEOSell3,000$27.42$82,260.00View SEC Filing  
3/21/2017Jeffrey H BurbankCEOSell3,000$27.72$83,160.00View SEC Filing  
3/20/2017Winifred L SwanSVPSell15,723$27.66$434,898.18View SEC Filing  
3/16/2017Craig W MooreDirectorSell1,000$27.93$27,930.00View SEC Filing  
3/8/2017Joseph E Turk JrPresidentSell1,000$27.53$27,530.00View SEC Filing  
3/7/2017Robert S BrownInsiderSell20,000$27.75$555,000.00View SEC Filing  
3/6/2017Robert S BrownInsiderSell6,390$28.01$178,983.90View SEC Filing  
2/23/2017Jeffrey H BurbankCEOSell7,500$28.97$217,275.00View SEC Filing  
2/22/2017Jeffrey H BurbankCEOSell7,500$29.01$217,575.00View SEC Filing  
2/17/2017Joseph E Turk JrPresidentSell6,000$29.66$177,960.00View SEC Filing  
2/15/2017Winifred L SwanSVPSell16,049$28.01$449,532.49View SEC Filing  
2/14/2017Robert S BrownInsiderSell2,448$28.28$69,229.44View SEC Filing  
2/10/2017Joseph E Turk JrPresidentSell3,500$28.36$99,260.00View SEC Filing  
2/8/2017Robert S BrownInsiderSell3,054$27.61$84,320.94View SEC Filing  
2/7/2017Robert S BrownInsiderSell3,117$27.54$85,842.18View SEC Filing  
2/6/2017Robert S BrownInsiderSell16,283$26.87$437,524.21View SEC Filing  
2/2/2017Joseph E Turk JrPresidentSell15,669$26.19$410,371.11View SEC Filing  
2/2/2017Robert S BrownInsiderSell37,347$26.68$996,417.96View SEC Filing  
1/26/2017Robert S BrownInsiderSell42,000$26.05$1,094,100.00View SEC Filing  
1/23/2017Robert S BrownInsiderSell21,615$26.20$566,313.00View SEC Filing  
1/20/2017Matthew W TowseSVPSell4,300$26.19$112,617.00View SEC Filing  
1/18/2017Jeffrey H BurbankCEOSell7,500$27.63$207,225.00View SEC Filing  
1/18/2017Robert S BrownInsiderSell8,183$27.58$225,687.14View SEC Filing  
1/17/2017Jeffrey H BurbankCEOSell7,500$27.52$206,400.00View SEC Filing  
1/17/2017Robert S BrownInsiderSell10,805$27.72$299,514.60View SEC Filing  
1/13/2017Joseph E Turk JrPresidentSell7,500$28.00$210,000.00View SEC Filing  
1/11/2017Joseph E Turk JrPresidentSell1,000$27.77$27,770.00View SEC Filing  
12/20/2016Matthew W TowseSVPSell4,300$25.55$109,865.00View SEC Filing  
12/15/2016Winifred L SwanSVPSell3,500$25.91$90,685.00View SEC Filing  
12/14/2016Jeffrey H BurbankCEOSell7,500$25.68$192,600.00View SEC Filing  
12/13/2016Jeffrey H BurbankCEOSell7,500$25.42$190,650.00View SEC Filing  
12/13/2016Joseph E Turk JrPresidentSell1,000$25.42$25,420.00View SEC Filing  
11/28/2016Joseph E Turk JrPresidentSell12,169$26.01$316,515.69View SEC Filing  
11/23/2016Jeffrey H BurbankCEOSell7,500$24.01$180,075.00View SEC Filing  
11/22/2016Jeffrey H BurbankCEOSell7,500$25.51$191,325.00View SEC Filing  
11/22/2016Winifred L SwanSVPSell3,000$25.51$76,530.00View SEC Filing  
11/21/2016Daniel A GianniniDirectorSell6,449$25.96$167,416.04View SEC Filing  
11/21/2016Matthew W TowseSVPSell4,300$26.23$112,789.00View SEC Filing  
11/17/2016Joseph E Turk JrPresidentSell1,000$25.97$25,970.00View SEC Filing  
11/16/2016Joseph E Turk JrPresidentSell22,500$26.26$590,850.00View SEC Filing  
9/14/2016Craig W MooreDirectorSell3,000$23.31$69,930.00View SEC Filing  
5/12/2016Joseph E Turk JrPresidentSell1,500$17.89$26,835.00View SEC Filing  
5/10/2016Joseph E Turk JrPresidentSell1,057$18.00$19,026.00View SEC Filing  
4/21/2016Joseph E Turk JrPresidentSell2,000$15.73$31,460.00View SEC Filing  
4/14/2016Winifred L SwanSVPSell6,260$16.40$102,664.00View SEC Filing  
4/5/2016Joseph E Turk JrPresidentSell2,500$15.05$37,625.00View SEC Filing  
3/22/2016Joseph E Turk JrPresidentSell2,000$14.34$28,680.00View SEC Filing  
3/14/2016Winifred L SwanSVPSell620$15.69$9,727.80View SEC Filing  
3/10/2016Joseph E Turk JrPresidentSell2,500$15.58$38,950.00View SEC Filing  
2/24/2016Barry M StraubeDirectorBuy1,500$14.20$21,300.00View SEC Filing  
2/24/2016Joseph E Turk JrPresidentSell2,992$14.12$42,247.04View SEC Filing  
2/16/2016Winifred L. SwanSVPSell2,500$14.07$35,175.00View SEC Filing  
2/12/2016Earl R. LewisDirectorBuy21,000$14.63$307,230.00View SEC Filing  
2/10/2016Joseph E. Turk, Jr.PresidentSell991$16.25$16,103.75View SEC Filing  
2/9/2016Joseph E. Turk, Jr.PresidentSell2,500$16.88$42,200.00View SEC Filing  
2/4/2016Joseph E. Turk, Jr.PresidentSell991$19.60$19,423.60View SEC Filing  
1/20/2016Joseph E Turk JrPresidentSell2,000$18.75$37,500.00View SEC Filing  
1/14/2016Winifred L. SwanSVPSell620$19.04$11,804.80View SEC Filing  
1/11/2016Matthew W. TowseSVPSell3,472$20.40$70,828.80View SEC Filing  
1/8/2016Joseph E. Turk, Jr.PresidentSell1,500$21.03$31,545.00View SEC Filing  
1/7/2016Joseph E. Turk, Jr.PresidentSell3,713$20.78$77,156.14View SEC Filing  
12/22/2015Joseph E. Turk, Jr.PresidentSell5,000$20.92$104,600.00View SEC Filing  
12/16/2015Joseph E. Turk, Jr.PresidentSell800$19.99$15,992.00View SEC Filing  
12/15/2015Matthew W. TowseSVPSell2,863$19.51$55,857.13View SEC Filing  
12/14/2015Winifred L. SwanSVPSell2,500$18.90$47,250.00View SEC Filing  
12/10/2015Jeffrey H. BurbankCEOSell9,274$18.94$175,649.56View SEC Filing  
12/8/2015Joseph E. Turk, Jr.PresidentSell2,913$19.38$56,453.94View SEC Filing  
11/20/2015Craig W MooreDirectorSell1,000$20.00$20,000.00View SEC Filing  
11/19/2015Joseph E Turk JrPresidentSell2,000$19.65$39,300.00View SEC Filing  
11/18/2015Craig W MooreDirectorSell4,000$19.60$78,400.00View SEC Filing  
11/16/2015Winifred L. SwanSVPSell2,500$19.65$49,125.00View SEC Filing  
11/12/2015Joseph E. Turk, Jr.PresidentSell4,055$20.44$82,884.20View SEC Filing  
11/10/2015Jeffrey H. BurbankCEOSell10,000$20.75$207,500.00View SEC Filing  
11/10/2015Joseph E. Turk, Jr.PresidentSell7,500$21.03$157,725.00View SEC Filing  
11/10/2015Matthew W. TowseSVPSell2,863$20.32$58,176.16View SEC Filing  
11/9/2015Daniel A GianniniDirectorSell6,593$20.30$133,837.90View SEC Filing  
11/9/2015Jeffrey H. BurbankCEOSell10,000$20.32$203,200.00View SEC Filing  
11/4/2015Joseph E. Turk, Jr.PresidentSell4,826$19.62$94,686.12View SEC Filing  
11/4/2015Matthew W. TowseSVPSell8,591$19.50$167,524.50View SEC Filing  
11/3/2015Robert S. BrowninsiderSell44,400$19.00$843,600.00View SEC Filing  
10/20/2015Joseph E. Turk, Jr.PresidentSell2,000$15.80$31,600.00View SEC Filing  
10/16/2015Jeffrey H. BurbankCEOSell10,000$15.59$155,900.00View SEC Filing  
10/15/2015Jeffrey H. BurbankCEOSell10,000$14.98$149,800.00View SEC Filing  
10/14/2015Winifred L. SwanSVPSell2,500$15.46$38,650.00View SEC Filing  
10/8/2015Joseph E. Turk, Jr.PresidentSell2,839$15.42$43,777.38View SEC Filing  
9/24/2015Joseph E Turk JrPresidentSell2,000$17.26$34,520.00View SEC Filing  
9/17/2015Jeffrey H. BurbankCEOSell10,000$16.18$161,800.00View SEC Filing  
9/16/2015Jeffrey H. BurbankCEOSell10,000$15.99$159,900.00View SEC Filing  
9/15/2015Craig W MooreDirectorSell1,000$16.00$16,000.00View SEC Filing  
9/14/2015Winifred L. SwanSVPSell2,500$16.01$40,025.00View SEC Filing  
9/9/2015Joseph E. Turk, Jr.PresidentSell2,839$16.54$46,957.06View SEC Filing  
8/25/2015Joseph E Turk JrPresidentSell2,000$18.25$36,500.00View SEC Filing  
8/17/2015Robert S BrownInsiderSell10,825$18.30$198,097.50View SEC Filing  
8/14/2015Winifred L SwanSVPSell2,500$18.14$45,350.00View SEC Filing  
8/13/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
8/12/2015Jeffrey H BurbankCEOSell10,000$18.03$180,300.00View SEC Filing  
8/12/2015Joseph E Turk JrPresidentSell3,252$17.74$57,690.48View SEC Filing  
7/22/2015Joseph E Turk JrPresidentSell2,000$13.86$27,720.00View SEC Filing  
7/14/2015Winifred L SwanSVPSell2,500$14.71$36,775.00View SEC Filing  
6/23/2015Joseph E Turk JrPresidentSell2,000$15.36$30,720.00View SEC Filing  
6/18/2015Jeffrey H BurbankCEOSell20,000$15.56$311,200.00View SEC Filing  
6/15/2015Winifred L SwanSVPSell2,500$15.48$38,700.00View SEC Filing  
6/10/2015Joseph E Turk JrPresidentSell2,839$16.00$45,424.00View SEC Filing  
5/18/2015Winifred L SwanSVPSell2,500$16.65$41,625.00View SEC Filing  
5/12/2015Jeffrey H BurbankCEOSell10,000$16.44$164,400.00View SEC Filing  
4/21/2015Joseph E Turk JrPresidentSell1,950$18.40$35,880.00View SEC Filing  
4/17/2015Jeffrey H BurbankCEOSell10,000$18.08$180,800.00View SEC Filing  
4/16/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
4/8/2015Joseph E Turk JrPresidentSell1,500$18.34$27,510.00View SEC Filing  
3/26/2015Joseph E Turk JrPresidentSell1,150$16.94$19,481.00View SEC Filing  
3/18/2015Jeffrey H BurbankCEOSell20,000$17.40$348,000.00View SEC Filing  
3/10/2015Joseph E Turk JrPresidentSell1,500$16.44$24,660.00View SEC Filing  
2/25/2015Joseph E Turk JrPresidentSell2,082$17.88$37,226.16View SEC Filing  
1/27/2015Joseph E Turk JrPresidentSell2,350$18.70$43,945.00View SEC Filing  
1/14/2015Winifred L SwanSVPSell500$18.44$9,220.00View SEC Filing  
1/13/2015Joseph E Turk JrPresidentSell1,500$18.35$27,525.00View SEC Filing  
1/13/2015Winifred L SwanSVPSell666$18.35$12,221.10View SEC Filing  
12/29/2014Winifred L SwanSVPSell667$18.17$12,119.39View SEC Filing  
12/23/2014Joseph E Turk JrPresidentSell2,350$18.44$43,334.00View SEC Filing  
12/15/2014Joseph E Turk JrPresidentSell2,000$17.45$34,900.00View SEC Filing  
12/15/2014Kevin HershbergerCAOSell8,000$17.19$137,520.00View SEC Filing  
12/10/2014Joseph E Turk JrPresidentSell1,500$17.77$26,655.00View SEC Filing  
12/5/2014Jeffrey H BurbankCEOSell5,000$17.16$85,800.00View SEC Filing  
12/2/2014Robert S BrownInsiderSell34,700$17.44$605,168.00View SEC Filing  
12/1/2014Joseph E Turk JrPresidentSell24,762$17.04$421,944.48View SEC Filing  
12/1/2014Winifred L SwanSVPSell16,667$17.04$284,005.68View SEC Filing  
11/25/2014Joseph E Turk JrPresidentSell3,350$17.59$58,926.50View SEC Filing  
11/14/2014Joseph E Turk JrPresidentSell29,560$17.39$514,048.40View SEC Filing  
11/14/2014Winifred L SwanSVPSell17,167$17.37$298,190.79View SEC Filing  
11/12/2014Joseph E Turk JrPresidentSell26,261$16.27$427,266.47View SEC Filing  
11/12/2014Kevin HershbergerCAOSell11,056$16.58$183,308.48View SEC Filing  
11/7/2014Joseph E Turk JrPresidentSell24,761$16.25$402,366.25View SEC Filing  
11/3/2014Joseph E Turk JrPresidentSell5,717$15.50$88,613.50View SEC Filing  
10/23/2014Joseph E Turk JrPresidentSell3,550$14.55$51,652.50View SEC Filing  
10/23/2014Robert S BrownInsiderSell45,370$14.53$659,226.10View SEC Filing  
9/24/2014Joseph E Turk JrPresidentSell3,550$13.34$47,357.00View SEC Filing  
9/19/2014Jeffrey H BurbankCEOSell2,416$14.00$33,824.00View SEC Filing  
9/19/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
9/10/2014Kevin HershbergerCAOSell843$13.58$11,447.94View SEC Filing  
9/8/2014Jeffrey H BurbankCEOSell2,322$14.00$32,508.00View SEC Filing  
9/8/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
8/27/2014Joseph E Turk JrPresidentSell2,550$13.06$33,303.00View SEC Filing  
8/15/2014Winifred L SwanSVPSell2,500$13.60$34,000.00View SEC Filing  
8/7/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
8/7/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
7/24/2014Joseph E Turk JrPresidentSell3,550$13.50$47,925.00View SEC Filing  
7/18/2014Winifred L SwanSVPSell2,000$13.46$26,920.00View SEC Filing  
6/24/2014Joseph E Turk JrPresidentSell3,950$14.43$56,998.50View SEC Filing  
6/20/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/17/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/9/2014Winifred L SwanSVPSell9,228$14.00$129,192.00View SEC Filing  
6/5/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/5/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/5/2014Winifred L SwanSVPSell7,500$14.00$105,000.00View SEC Filing  
5/29/2014Joseph E Turk JrPresidentSell4,035$13.60$54,876.00View SEC Filing  
5/15/2014Winifred SwanSVPSell9,629$12.80$123,251.20View SEC Filing  
5/14/2014Winifred SwanSVPSell5,000$13.04$65,200.00View SEC Filing  
3/6/2014Robert FunariDirectorBuy10,150$14.72$149,408.00View SEC Filing  
10/21/2013Robert S BrownInsiderSell140,100$14.00$1,961,400.00View SEC Filing  
9/9/2013Thomas SheaSVPSell1,000$12.30$12,300.00View SEC Filing  
8/12/2013Thomas SheaSVPSell1,172$12.93$15,153.96View SEC Filing  
7/8/2013Thomas SheaSVPSell7,000$14.34$100,380.00View SEC Filing  
6/10/2013Thomas SheaSVPSell5,000$13.73$68,650.00View SEC Filing  
5/13/2013Thomas SheaSVPSell15,724$12.67$199,223.08View SEC Filing  
11/13/2012David S UtterbergDirectorSell184,204$11.58$2,133,082.32View SEC Filing  
11/2/2012David S UtterbergDirectorSell34,730$11.13$386,544.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NxStage Medical (NASDAQ:NXTM)
Latest Headlines for NxStage Medical (NASDAQ:NXTM)
Source:
DateHeadline
americanbankingnews.com logo Analysts Expect NxStage Medical, Inc. (NXTM) Will Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - July 27 at 9:30 AM
americanbankingnews.com logoInsider Selling: NxStage Medical, Inc. (NXTM) SVP Sells 4,300 Shares of Stock
www.americanbankingnews.com - July 21 at 7:51 PM
americanbankingnews.com logoHead-To-Head Analysis: Analogic Corporation (ALOG) versus NxStage Medical (NXTM)
www.americanbankingnews.com - July 18 at 2:44 PM
americanbankingnews.com logoReviewing Analogic Corporation (ALOG) and NxStage Medical (NASDAQ:NXTM)
www.americanbankingnews.com - July 15 at 8:06 AM
finance.yahoo.com logoETFs with exposure to NxStage Medical, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:03 AM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - July 14 at 12:46 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 6:48 PM
finance.yahoo.com logoNxStage® to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 11 at 6:15 AM
americanbankingnews.com logoFinancial Comparison: NxStage Medical (NASDAQ:NXTM) & Analogic Corporation (ALOG)
www.americanbankingnews.com - July 10 at 10:12 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) President Joseph E. Turk, Jr. Sells 1,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoJoseph E. Turk, Jr. Sells 1,000 Shares of NxStage Medical, Inc. (NXTM) Stock
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoCritical Contrast: NxStage Medical (NXTM) versus EndoChoice Holdings (GI)
www.americanbankingnews.com - July 2 at 12:04 PM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) Expected to Post Quarterly Sales of $96.78 Million
www.americanbankingnews.com - July 2 at 7:32 AM
americanbankingnews.com logo-$0.03 EPS Expected for NxStage Medical, Inc. (NASDAQ:NXTM) This Quarter
www.americanbankingnews.com - July 1 at 12:12 AM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) Upgraded at BidaskClub
www.americanbankingnews.com - June 30 at 9:08 PM
finance.yahoo.com logoNxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : June 28, 2017
finance.yahoo.com - June 28 at 1:59 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Earns Buy Rating from Analysts at Craig Hallum
www.americanbankingnews.com - June 27 at 12:58 PM
finance.yahoo.com logoETFs with exposure to NxStage Medical, Inc. : June 26, 2017
finance.yahoo.com - June 27 at 6:54 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Matthew W. Towse Sells 4,300 Shares
www.americanbankingnews.com - June 21 at 8:04 PM
americanbankingnews.com logoHead-To-Head Analysis: NxStage Medical (NXTM) versus Avinger (AVGR)
www.americanbankingnews.com - June 17 at 2:08 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Sells $80,990.00 in Stock
www.americanbankingnews.com - June 16 at 7:58 PM
finance.yahoo.com logoETFs with exposure to NxStage Medical, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 7:56 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 16 at 5:00 PM
finance.yahoo.com logoNxStage Launches 3rd Annual Nurse Hero Contest to Celebrate Home Hemodialysis Nurses
finance.yahoo.com - June 16 at 8:23 AM
finance.yahoo.com logoNxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 4:22 PM
americanbankingnews.com logoEndoChoice Holdings (GI) versus NxStage Medical (NXTM) Head-To-Head Comparison
www.americanbankingnews.com - June 13 at 10:35 PM
americanbankingnews.com logoHead-To-Head Analysis: NxStage Medical (NXTM) vs. EndoChoice Holdings (GI)
www.americanbankingnews.com - June 12 at 8:56 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $96.78 Million
www.americanbankingnews.com - June 8 at 9:30 AM
americanbankingnews.com logoZacks: Brokerages Expect NxStage Medical, Inc. (NXTM) to Post -$0.03 EPS
www.americanbankingnews.com - June 6 at 10:28 PM
americanbankingnews.com logoReviewing NxStage Medical (NXTM) & EndoChoice Holdings (GI)
www.americanbankingnews.com - June 6 at 7:24 AM
streetinsider.com logoNxstage Medical (NXTM) Says New Data from KIHDNEy Cohort Shows Improved Biochemical Outcomes - StreetInsider.com
www.streetinsider.com - June 5 at 12:07 AM
streetinsider.com logoNxstage Medical (NXTM) Says New Data from KIHDNEy Cohort Shows Improved Biochemical Outcomes
www.streetinsider.com - June 2 at 8:53 PM
finance.yahoo.com logoNew Data from KIHDNEy Cohort Shows Improved Biochemical Outcomes and Broad Range Patient Suitability with More Frequent Hemodialysis Using the NxStage System One
finance.yahoo.com - June 2 at 8:53 PM
finance.yahoo.com logoNxStage Announces Second Quarter 2017 Investor Conference Schedule
finance.yahoo.com - May 26 at 5:23 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Sells $91,848.00 in Stock
www.americanbankingnews.com - May 23 at 8:18 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 4:04 PM
bizjournals.com logoResearch Reports Initiation on Medical Equipment Stocks -- Masimo, NovoCure, Nxstage Medical, and Varex Imaging
www.bizjournals.com - May 22 at 9:48 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Sells $76,790.00 in Stock
www.americanbankingnews.com - May 15 at 8:21 PM
finance.yahoo.com logoEdited Transcript of NXTM earnings conference call or presentation 9-May-17 1:00pm GMT
finance.yahoo.com - May 15 at 10:03 AM
americanbankingnews.com logo$96.7 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - May 13 at 9:40 AM
americanbankingnews.com logoLeerink Swann Research Analysts Lower Earnings Estimates for NxStage Medical, Inc. (NXTM)
www.americanbankingnews.com - May 12 at 12:32 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Expected to Earn Q2 2017 Earnings of ($0.03) Per Share
www.americanbankingnews.com - May 12 at 8:51 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for NxStage Medical, Inc. (NXTM) Reduced by William Blair
www.americanbankingnews.com - May 12 at 8:50 AM
americanbankingnews.com logoQ2 2018 EPS Estimates for NxStage Medical, Inc. (NXTM) Cut by Analyst
www.americanbankingnews.com - May 11 at 2:14 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Expected to Post Q3 2017 Earnings of ($0.01) Per Share
www.americanbankingnews.com - May 11 at 9:52 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for NxStage Medical, Inc. (NXTM) Cut by Analyst
www.americanbankingnews.com - May 11 at 9:52 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - May 11 at 8:20 AM
streetinsider.com logoNxstage Medical (NXTM) Reports FDA Clearance for iNew System One Hemodialysis System - StreetInsider.com
www.streetinsider.com - May 11 at 12:11 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 10 at 7:36 PM
streetinsider.com logoNxstage Medical (NXTM) Reports FDA Clearance for iNew System One Hemodialysis System
www.streetinsider.com - May 10 at 7:09 PM

Social

Chart

NxStage Medical (NXTM) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff